PRISM BioLab Co

PRISM BioLab Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of PRISM BioLab Co (206A.T) as of Nov 9, 2026 is -4.98. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 48.71 — a change of -110.23% (lower).

P/CF

-4.98

YoY

-110.23%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of PRISM BioLab Co is 2025 -4.98 . P/CF (Price-to-Cash-Flow Ratio) of PRISM BioLab Co was 2024 48.71 . It decreases by -110.23% lower compared to the previous year.

The PRISM BioLab Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2022
71.03 JPY
Jan 1, 2023
-14.23 JPY
Jan 1, 2024
48.71 JPY
Jan 1, 2025
-4.98 JPY
The PRISM BioLab Co P/CF history
YEARP/CFYoY
-4.98-110.23%
48.71-442.21%
-14.23-120.04%
71.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

P/CF (Price-to-Cash-Flow Ratio) of PRISM BioLab Co is -4.98 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of PRISM BioLab Co changed from 48.71 to -4.98, representing a -110.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s PRISM BioLab Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co